BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wang R, Tang R, Li B, Ma X, Schnabl B, Tilg H. Gut microbiome, liver immunology, and liver diseases.Cell Mol Immunol. 2021;18:4-17. [PMID: 33318628 DOI: 10.1038/s41423-020-00592-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Knorr J, Wree A, Feldstein AE. Pyroptosis in Steatohepatitis and Liver Diseases. J Mol Biol 2021;:167271. [PMID: 34592216 DOI: 10.1016/j.jmb.2021.167271] [Reference Citation Analysis]
2 Lustig RH, Collier D, Kassotis C, Roepke TA, Ji Kim M, Blanc E, Barouki R, Bansal A, Cave MC, Chatterjee S, Choudhury M, Gilbertson M, Lagadic-Gossmann D, Howard S, Lind L, Tomlinson CR, Vondracek J, Heindel JJ. Obesity I: Overview and molecular and biochemical mechanisms. Biochem Pharmacol 2022;:115012. [PMID: 35393120 DOI: 10.1016/j.bcp.2022.115012] [Reference Citation Analysis]
3 De Muynck K, Vanderborght B, Van Vlierberghe H, Devisscher L. The Gut-Liver Axis in Chronic Liver Disease: A Macrophage Perspective. Cells 2021;10:2959. [PMID: 34831182 DOI: 10.3390/cells10112959] [Reference Citation Analysis]
4 Han H, Jiang Y, Wang M, Melaku M, Liu L, Zhao Y, Everaert N, Yi B, Zhang H. Intestinal dysbiosis in nonalcoholic fatty liver disease (NAFLD): focusing on the gut-liver axis. Crit Rev Food Sci Nutr 2021;:1-18. [PMID: 34404276 DOI: 10.1080/10408398.2021.1966738] [Reference Citation Analysis]
5 Simbrunner B, Trauner M, Reiberger T. Review article: therapeutic aspects of bile acid signalling in the gut-liver axis. Aliment Pharmacol Ther 2021;54:1243-62. [PMID: 34555862 DOI: 10.1111/apt.16602] [Reference Citation Analysis]
6 Di Giacomo S, Briz O, Vitalone A, Di Sotto A. Editorial: Natural Products and Hepatic Health: Light and Shadows. Front Pharmacol 2022;13:868207. [DOI: 10.3389/fphar.2022.868207] [Reference Citation Analysis]
7 Bertolini A, Fiorotto R, Strazzabosco M. Bile acids and their receptors: modulators and therapeutic targets in liver inflammation. Semin Immunopathol 2022. [PMID: 35415765 DOI: 10.1007/s00281-022-00935-7] [Reference Citation Analysis]
8 Blesl A, Stadlbauer V. The Gut-Liver Axis in Cholestatic Liver Diseases. Nutrients 2021;13:1018. [PMID: 33801133 DOI: 10.3390/nu13031018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Mantovani A, Petracca G, Beatrice G, Csermely A, Tilg H, Byrne CD, Targher G. Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies. Gut 2021:gutjnl-2021-324191. [PMID: 33685968 DOI: 10.1136/gutjnl-2021-324191] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
10 Fujimoto Y, Kaji K, Nishimura N, Enomoto M, Murata K, Takeda S, Takaya H, Kawaratani H, Moriya K, Namisaki T, Akahane T, Yoshiji H. Dual therapy with zinc acetate and rifaximin prevents from ethanol-induced liver fibrosis by maintaining intestinal barrier integrity. World J Gastroenterol 2021; 27(48): 8323-8342 [DOI: 10.3748/wjg.v27.i48.8323] [Reference Citation Analysis]
11 Bozward AG, Ronca V, Osei-Bordom D, Oo YH. Gut-Liver Immune Traffic: Deciphering Immune-Pathogenesis to Underpin Translational Therapy. Front Immunol 2021;12:711217. [PMID: 34512631 DOI: 10.3389/fimmu.2021.711217] [Reference Citation Analysis]
12 Feng D, Gao B. From basic liver immunology to therapeutic opportunities for liver diseases. Cell Mol Immunol 2021;18:1-3. [PMID: 33339875 DOI: 10.1038/s41423-020-00607-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Huang MX, Yang SY, Luo PY, Long J, Liu QZ, Wang J, He Y, Li L, Zhao ZB, Lian ZX. Gut microbiota contributes to sexual dimorphism in murine autoimmune cholangitis. J Leukoc Biol 2021. [PMID: 34047390 DOI: 10.1002/JLB.3MA0321-037R] [Reference Citation Analysis]
14 Yu Y, Liu B, Liu X, Zhang X, Zhang W, Tian H, Shui G, Wang W, Song M, Wang J. Mesenteric lymph system constitutes the second route in gut-liver axis and transports metabolism-modulating gut microbial metabolites. Journal of Genetics and Genomics 2022. [DOI: 10.1016/j.jgg.2022.03.012] [Reference Citation Analysis]
15 Lin Z, Ma X. Dietary nutrients mediate crosstalk between bile acids and gut microbes in animal host metabolism. Crit Rev Food Sci Nutr 2022;:1-15. [PMID: 35507502 DOI: 10.1080/10408398.2022.2067118] [Reference Citation Analysis]
16 Qu L, Ma X, Fan D. Ginsenoside Rk3 Suppresses Hepatocellular Carcinoma Development through Targeting the Gut-Liver Axis. J Agric Food Chem 2021;69:10121-37. [PMID: 34415764 DOI: 10.1021/acs.jafc.1c03279] [Reference Citation Analysis]
17 Zhang L, Yang F, Li T, Dayananda B, Lin L, Lin C. Lessons from the diet: Captivity and sex shape the gut microbiota in an oviparous lizard ( Calotes versicolor ). Ecology and Evolution 2022;12. [DOI: 10.1002/ece3.8586] [Reference Citation Analysis]
18 Lee NY, Suk KT. The Role of the Gut Microbiome in Liver Cirrhosis Treatment. Int J Mol Sci 2020;22:E199. [PMID: 33379148 DOI: 10.3390/ijms22010199] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
19 Cargill T, Culver EL. The Role of B Cells and B Cell Therapies in Immune-Mediated Liver Diseases. Front Immunol 2021;12:661196. [PMID: 33936097 DOI: 10.3389/fimmu.2021.661196] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Zhao Q, Song SY, Zhang YQ, Ren X, Zhang P, Li X, Fu XM, Wang CY. The underlying mechanisms of anti-hepatitis B effects of formula Le-Cao-Shi and its single herbs by network pharmacology and gut microbiota analysis. Biomed Pharmacother 2022;148:112692. [PMID: 35151160 DOI: 10.1016/j.biopha.2022.112692] [Reference Citation Analysis]
21 Tuganbaev T, Honda K. Non-zero-sum microbiome immune system interactions. Eur J Immunol 2021;51:2120-36. [PMID: 34242413 DOI: 10.1002/eji.202049065] [Reference Citation Analysis]
22 Raskov H, Orhan A, Gaggar S, Gögenur I. Neutrophils and polymorphonuclear myeloid-derived suppressor cells: an emerging battleground in cancer therapy. Oncogenesis 2022;11:22. [PMID: 35504900 DOI: 10.1038/s41389-022-00398-3] [Reference Citation Analysis]
23 Won SM, Park E, Jeong JJ, Ganesan R, Gupta H, Gebru YA, Sharma S, Kim DJ, Suk KT. The Gut Microbiota-Derived Immune Response in Chronic Liver Disease. Int J Mol Sci 2021;22:8309. [PMID: 34361075 DOI: 10.3390/ijms22158309] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
24 Sharma SP, Suk KT, Kim DJ. Significance of gut microbiota in alcoholic and non-alcoholic fatty liver diseases. World J Gastroenterol 2021; 27(37): 6161-6179 [PMID: 34712025 DOI: 10.3748/wjg.v27.i37.6161] [Reference Citation Analysis]
25 Milosevic I, Russo E, Vujovic A, Barac A, Stevanovic O, Gitto S, Amedei A. Microbiota and viral hepatitis: State of the art of a complex matter. World J Gastroenterol 2021; 27(33): 5488-5501 [PMID: 34588747 DOI: 10.3748/wjg.v27.i33.5488] [Reference Citation Analysis]
26 Zhu L, Li B, Chen D, Chen N, Xu L, Li Q, Chen X. sSTEAP4 regulates cellular homeostasis and improves high-fat-diet-caused oxidative stress in hepatocytes. Life Sciences 2022;296:120438. [DOI: 10.1016/j.lfs.2022.120438] [Reference Citation Analysis]
27 Arun KB, Madhavan A, Sindhu R, Emmanual S, Binod P, Pugazhendhi A, Sirohi R, Reshmy R, Awasthi MK, Gnansounou E, Pandey A. Probiotics and gut microbiome - Prospects and challenges in remediating heavy metal toxicity. J Hazard Mater 2021;420:126676. [PMID: 34329091 DOI: 10.1016/j.jhazmat.2021.126676] [Reference Citation Analysis]
28 de Vos WM, Tilg H, Van Hul M, Cani PD. Gut microbiome and health: mechanistic insights. Gut. [DOI: 10.1136/gutjnl-2021-326789] [Reference Citation Analysis]
29 Peng W, Li H, Zhao X, Shao B, Zhu K. Pyocyanin Modulates Gastrointestinal Transformation and Microbiota. J Agric Food Chem 2022. [PMID: 35171599 DOI: 10.1021/acs.jafc.1c07726] [Reference Citation Analysis]
30 Shu W, Shanjian C, Jinpiao L, Qishui O. Gut microbiota dysbiosis in patients with hepatitis B virus-related cirrhosis. Annals of Hepatology 2022. [DOI: 10.1016/j.aohep.2022.100676] [Reference Citation Analysis]
31 Wu LL, Huang TS, Shyu YC, Wang CL, Wang HY, Chen PJ. Gut microbiota in the innate immunity against hepatitis B virus - implication in age-dependent HBV clearance. Curr Opin Virol 2021;49:194-202. [PMID: 34242953 DOI: 10.1016/j.coviro.2021.06.006] [Reference Citation Analysis]
32 Gu X, Lu Q, Zhang C, Tang Z, Chu L. Clinical Application and Progress of Fecal Microbiota Transplantation in Liver Diseases: A Review. Semin Liver Dis 2021. [PMID: 34261137 DOI: 10.1055/s-0041-1732319] [Reference Citation Analysis]
33 Zhou Z, Sun B, Yu D, Zhu C. Gut Microbiota: An Important Player in Type 2 Diabetes Mellitus. Front Cell Infect Microbiol 2022;12:834485. [DOI: 10.3389/fcimb.2022.834485] [Reference Citation Analysis]
34 Harkus U, Wankell M, Palamuthusingam P, Mcfarlane C, Hebbard L. Immune checkpoint inhibitors in HCC: cellular, molecular and systemic data. Seminars in Cancer Biology 2022. [DOI: 10.1016/j.semcancer.2022.01.005] [Reference Citation Analysis]
35 Wu Y, Mo R, Zhang M, Zhou W, Li D. Grape Seed Proanthocyanidin Alleviates Intestinal Inflammation Through Gut Microbiota-Bile Acid Crosstalk in Mice. Front Nutr 2022;8:786682. [DOI: 10.3389/fnut.2021.786682] [Reference Citation Analysis]
36 Adams DH. Sinusoidal Endothelial Cells as Orchestrators of the Gut Liver Immune Axis. Hepatology 2021. [PMID: 33928673 DOI: 10.1002/hep.31873] [Reference Citation Analysis]